Compositions, methods of use, and methods of treatment
Embodiments of the present disclosure provide for compositions including an antimicrobial agent, pharmaceutical compositions including the composition or pharmaceutical composition, methods of treating a condition or disease, methods of treatment using compositions or pharmaceutical compositions, and the like.
1. A method of treating a disease or condition consisting of: administering to a subject in need thereof, a therapeutically effective amount of a COX-2 inhibitor, or a pharmaceutically acceptable salt of the COX-2 inhibitor, and a therapeutically effective amount of a cannabinoid, or a pharmaceutically acceptable salt of the cannabinoid, to treat the disease or condition.
2. The method of claim 1 , wherein administering includes administering to the subject a pharmaceutical composition including both: a therapeutically effective amount of a COX-2 inhibitor, or a pharmaceutically acceptable salt of the COX-2 inhibitor; and a therapeutically effective amount a cannabinoid, or a pharmaceutically acceptable salt of the cannabinoid.
3. The method of claim 2 , wherein the cannabinoid is formulated in a delayed-release cannabinoid formulation.
4. The method of claim 1 , wherein the cannabinoid is administered about 15 minutes or more after the initial administration of the COX-2 inhibitor.
5. The method of claim 1 , wherein administering includes:
administering to the subject, a first pharmaceutical composition that includes a therapeutically effective amount of a COX-2 inhibitor, or a pharmaceutically acceptable salt of the COX-2 inhibitor and a pharmaceutically acceptable carrier, and
administering to the subject a second pharmaceutical composition that includes a therapeutically effective amount of a cannabinoid, or a pharmaceutically acceptable salt of the cannabinoid, and a pharmaceutically acceptable carrier.
6. The method of claim 5 , wherein the second pharmaceutical composition is delivered about 15 minutes after the first pharmaceutical composition.
7. The method of claim 1 , wherein the COX-2 inhibitor is selected from the group consisting of: celecoxib, rofecoxib, meloxicam, piroxicam, deracoxib, parecoxib, valdecoxib, etoricoxib, a chromene derivative, a chroman derivative, N-(2-cyclohexyloxynitrophenyl)methane sulfonamide, COX189, ABT963, JTE-522, rofecoxib, valdecoxib, parecoxib, aspirin, acetaminophen, ibuprofen, flurbiprofen, ketoprofen, naproxen, oxaprozin, etodolac, indomethacin, ketorolac, lornoxicam, nabumetone, and diclofenac, as well as pharmaceutically acceptable salts of each, pharmaceutically acceptable derivatives of each, prodrugs of each.
8. The method of claim 1 , wherein the cannabinoid is selected from the group consisting of: dronabinol, nabilone, cannabinol (CBN), tetrahydrocannabinol (THC), dimethyl heptylpentyl cannabidiol (DMHP-CBD), and a combination thereof.
9. The method of claim 1 , wherein the COX-2 inhibitor is celecoxib or rofecoxib and the cannabinoid is dronabinol or nabilone.
10. The method of claim 1 , wherein the disease or condition is selected from the group consisting of: Alzheimer's disease, Parkinson's disease, multiple sclerosis, epilepsy, traumatic brain injury, brain ischemia (stroke), arthritis, cancer, asthma, bronchitis asthma, bronchitis, inflammatory bowel disease, Crohn's disease, gastritis, irritable bowel syndrome, ulcerative colitis, migraine headaches, periarteritis nodosa , thyroiditis, aplastic anemia, Hodgkin's disease, sclerodma, rheumatic fever, type II diabetes, myasthenia gravis, amyotrophic lateral sclerosis, sacoidosis, nephrotic syndrome, Behchet's syndrome, polymyositis, gingivitis, peridontal disease, fibromyalgia, atopic dermatitis, insulitis, nausea, anorexia, pain, and post-traumatic stress disorder.
11. A method of reducing a side-effect of a cannabinoid administered to a patient, consisting of the step of administering to the patient receiving the cannabinoid a therapeutically effective amount of a COX-2 inhibitor or a pharmaceutically acceptable salt thereof.
12. The method of claim 11 , wherein the COX-2 inhibitor or a pharmaceutically acceptable salt thereof and the cannabinoid or a pharmaceutically acceptable salt thereof are administered together in a single pharmaceutical composition.
13. The method of claim 11 , wherein the cannabinoid is formulated in a delayed-release cannabinoid formulation.
14. The method of claim 11 , wherein the cannabinoid is administered about 15 minutes or more after the initial administration of the COX-2 inhibitor.
15. The method of claim 11 , wherein administering includes:
administering to the subject, a first pharmaceutical composition that includes a therapeutically effective amount of a COX-2 inhibitor or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, and
administering to the subject a second pharmaceutical composition that includes a therapeutically effective amount of a cannabinoid or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
16. The method of claim 11 , wherein the COX-2 inhibitor is selected from the group consisting of: celecoxib, rofecoxib, meloxicam, piroxicam, deracoxib, parecoxib, valdecoxib, etoricoxib, a chromene derivative, a chroman derivative, N-(2-cyclohexyloxynitrophenyl)methane sulfonamide, COX189, ABT963, JTE-522, rofecoxib, valdecoxib, parecoxib, aspirin, acetaminophen, ibuprofen, flurbiprofen, ketoprofen, naproxen, oxaprozin, etodolac, indomethacin, ketorolac, lornoxicam, nabumetone, and diclofenac, as well as pharmaceutically acceptable salts of each, pharmaceutically acceptable derivatives of each, prodrugs of each.
17. The method of claim 16 , wherein the cannabinoid is selected from the group consisting of: dronabinol, nabilone, cannabinol (CBN), tetrahydrocannabinol (THC), dimethyl heptylpentyl cannabidiol (DMHP-CBD), and a combination thereof.
18. The method of claim 11 , wherein the COX-2 inhibitor is celecoxib or rofecoxib and the cannabinoid is dronabinol or nabilone.